Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MK0773-003 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic efficacy of MK0773 in healthy postmenopausal women.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Postmenopausal Women- Active Agent Group | Experimental |
| |
| Postmenopausal Women- Placebo | Placebo Comparator | Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MK 0773 | Drug | 25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants with Serious Clinical Adverse Events | From date of enrollment through 12 weeks of study | |
| Number of Participants with Nonerserious Clinical Adverse Events | From date of enrollment through 12 weeks of study | |
| Number of Participants with Serious Laboratory Adverse Events | From date of enrollment through 12 weeks of study | |
| Number of Participants with Nonserious Laboratory Adverse Events | From date of enrollment through 12 weeks of study | |
| Number of Participants Who Discontinued Due to Any Adverse Event | From date of enrollment through 12 weeks of study | |
| Number of Participants Who Withdrew Consent and Discontinued the Study | From date of enrollment through 12 weeks of study | |
| Least Squares Mean Change in Lean Body Mass | From baseline, at 12 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Merck Sharp & Dohme LLC | Study Director |
Not provided
Not provided
| ID | Term |
|---|---|
| D010024 | Osteoporosis |
| ID | Term |
|---|---|
| D001851 | Bone Diseases, Metabolic |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D008659 | Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C550076 | 3-fluoro-N-(3H-imidazo(4,5-b)pyridin-2-ylmethyl)-1,4a,6a-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno(5,4-f)quinoline-7-carboxamide |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Placebo oral tablet b.i.d for 12 weeks |
|
| D009750 |
| Nutritional and Metabolic Diseases |